Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline von Wilamowitz-Moellendorff

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Clinical Medicine|May 11, 2024
A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic SyndromesRalph Boccia, Hong Xiao, Caroline von Wilamowitz-Moellendorff, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 6, 2026
Pulmonary Function Decline in Alpha-1 Antitrypsin Deficiency: A Systematic Review and Meta-AnalysisAlice M Turner, Priscilla Wittkopf, Caroline von Wilamowitz-Moellendorff, et al.
Future Oncology (London, England)|July 7, 2026
Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC)Francesco Passiglia, Eugenia Priedane, Silvy Mardiguian, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Clinical Medicine|May 11, 2024
A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic SyndromesRalph Boccia, Hong Xiao, Caroline von Wilamowitz-Moellendorff, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 6, 2026
Pulmonary Function Decline in Alpha-1 Antitrypsin Deficiency: A Systematic Review and Meta-AnalysisAlice M Turner, Priscilla Wittkopf, Caroline von Wilamowitz-Moellendorff, et al.
Future Oncology (London, England)|July 7, 2026
Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC)Francesco Passiglia, Eugenia Priedane, Silvy Mardiguian, et al.
Pageof 1